On September 4, 2023 QIAGEN reported that it will host the Global Oncohematology Summit 2023, held on September 13 and 14, under the theme "I Can: Improving Patients’ Lives Through Oncohematology Testing and Research" (Press release, Qiagen, SEP 4, 2023, View Source;Improving-patients-lives-through-testing-and-research-/default.aspx [SID1234634863]). The virtual event unites experts and patients from around the globe to discuss the latest advances and challenges in oncohematology testing, blood cancer clinical care, and research, focusing on improving patient outcomes. Emphasizing the utmost importance of patients’ perspectives, the summit will feature their testimonies, bringing their voices and considerations to the forefront of the discussion.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Blood cancer continues to pose a significant global threat, with more than 470,000 new cases of leukemia in 2020 alone and nearly 312,000 deaths . With an overall 5-year relative survival rate in the US of 66.4% for all types of leukemia , early diagnosis and treatment are more crucial than ever. The Global Oncohematology Summit 2023 will be a vital platform for blood cancer clinical researchers, oncohematologists, data specialists, and survivors to exchange innovative ideas and insights in testing, clinical care and research.
"The QIAGEN Global Oncohematology Summit underscores our dedication to improving patient outcomes through collaboration, innovation, and education," said Jonathan Arnold, Vice President, Head of Translational Science and Precision Diagnostics at QIAGEN. "By bringing together experts from around the world, we aim to address the challenges that impact diagnosis, monitoring, and patient care, and ultimately, make a difference in the lives of those affected by blood cancers."
The event’s keynote speaker, Prof. Elias Jabbour, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, USA, said: "It is important to discuss and share the most innovative therapies in hematology from leukemia to myeloma, including assessing and managing measurable residual disease. There will be plenty of time for questions and answers and panel discussions where experts from around the globe will exchange their experiences."
The QIAGEN Global Oncohematology Summit 2023, which is expected to gather over 500 participants from across the world, is a free, educational virtual event that is CME and CPD-accredited. Event highlights include a diverse range of topics such as the latest blood cancer patient therapies management, expert views on CAR-T cell therapy and other breakthroughs, advocate and patient perspectives, new insights into testing and monitoring blood cancer and a European diagnostic laboratory’s perspective on their IVDR strategy.
To join the QIAGEN Global Oncohematology Summit on September 13 and 14, please register here.
QIAGEN: Advancing cancer diagnostics and research
Due to the vast biological and genetic diversity of hematological malignancies, identifying crucial molecular markers is essential for advancing blood cancer precision medicine and research. QIAGEN provides an extensive portfolio, encompassing sample collection to data interpretation. For example, the ipsogen assays provide diagnostic solutions, focusing on the detection of specific genetic and molecular biomarkers. These tests enable personalized care, early detection, treatment selection, response and monitoring, leading to more informed decisions and better patient care. QIAGEN ipsogen tests allow healthcare professionals to tailor treatment plans, assess measurable residual disease, and provide enhanced prognostic capabilities.
QIAGEN is also collaborating with more than 30 global pharmaceutical and biotechnology companies to develop and market companion diagnostics, which detect clinically relevant genetic abnormalities and provide insights that guide clinical decision-making in diseases like blood cancers. QIAGEN has an unmatched depth and breadth of technologies, from next-generation sequencing (NGS) to polymerase chain reaction (PCR) and digital PCR (dPCR) for companion diagnostic development.
You can find out more about QIAGEN’s blood cancer portfolio here.